WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 27-May-2016 (Data received as of 20-May-2016)
Next overall update Fall 2016
2015 data are provisionary
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 15'3801 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 26'6431 Child (under 5 years) mortality rate: 52

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 2'878  2'917  2'964  3'016  3'071  3'486  3'697  3'432 
Births 30  30  30  31  31  33  55  53 
Surviving infants 30  30  30  31  31  33  54  52 
Pop. less than 5 years 152  152  152  152  150  186  289  258 
Pop. less than 15 years 418  422  428  436  448  683  835  800 
Female 15-49 years 647  672  699  728  755  885  924  887 

Number of reported cases

(Click for retrospective incidence data for Lithuania)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart
  50  11  35  19 
Mumps
ChartChart
  39  45  67  62  64  4'377 
Pertussis
ChartChart
  60  143  65  154  30  91 
Polio*
ChartChart
 
Rubella
ChartChart
  1'304 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Lithuania)
Vaccine year result method % card seen                                                
BCG          97  98  98  98  98  99 
DTP1          97  97  97  97  95  99 
DTP3          93  93  93  93  92  94 
DTP4          90  89 
IPV1          97  97 
HepB_BD          97  98  96  96  99 
HepB3          94  94  93  93  95  99 
Hib3          93  93  93  93  92 
JapEnc         
MCV1          94  93  93  93  94  97 
MCV2          92  92  92  93  94  97 
PCV1         
PCV3         
Pol3          93  93  93  93  92  92 
Rota1         
RotaC         
Rubella1          94  93  93  93  94 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Lithuania)
BCG
ChartChart
  98  98  98  98  99 
DTP1
ChartChart
  97  97  97  95  99 
DTP3
ChartChart
  93  93  93  92  94 
HepB3
ChartChart
  94  93  93  95  98 
HepB_BD
ChartChart
  97  98  96  96  99 
Hib3
ChartChart
  93  93  93  92 
MCV1
ChartChart
  93  93  93  94  97 
MCV2
ChartChart
  92  92  93  94  97 
PCV3
ChartChart
 
Pol3
ChartChart
  93  93  93  92  92 
RotaC
ChartChart
 

Number of districts in the country 60  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 90
From 80 to 89% 8
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
2
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 3 days; Yes
DT 15-16 years; Yes
DTaPHibIPV 2, 4, 6, 18 months; Yes
DTaPIPV 6-7 years; Yes
HepB_Pediatric birth; 1, 6 months; Yes
Influenza_Adult >= 65 years; Yes and pregnant women, health care workers, adults with chronic diseases and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MMR 15-16 months; 6-7 years; Yes
Pneumo_conj 2, 4, 12-15 months; Yes
Tdap 15-16 years; Yes

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2014-2018  2009-2013  2009-2013  2009-2013  2009-2013  2009-2013  2006-2008 
Nº of districts with microplans that include activities to raise immunization coverage number 60  53  52  52  52  52  52 

System performance

Total Nº districts in country number 60  53  52  52  52  52  52 
Nº districts with DTP3 coverage >=80% number 58  52  52  51  52  52  51 
% of districts with DTP3 coverage >=80% From 0 to 100% 97  98  100  98  100  100  98 
Nº districts with measles (MCV1) coverage >=95% number 29  22  22  28  37  45  45 
% of districts with MCV1 coverage >=95% From 0 to 100% 48  42  42  54  71  87  87 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%   100  100  100    100   

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.